2 Human sample, from patients or healthy donors, are a valuable link between basic 3 research and clinic. Especially in translational research, they play an essential role in 4 understanding development and progression of diseases as well as in developing 5 new diagnostic and therapeutic tools. Stored in biobanks, fast access to appropriate 6 material becomes possible. However, biobanking in a clinical context faces several 7 challenges. In practice, collecting samples during clinical routine does not allow to 8 strictly adhere to protocols of sample collection in all aspects. This may influence 9 sample quality to variable degrees. Time from sample draw to asservation is a 10 variable factor, and influences of prolonged storage at ambient temperature of 11 tissues are not well understood. We investigated whether delays between 5 minutes 12 and 3 hours, and the use of RNAlater RNA-preserving reagent would lead to a 13 relevant drop in sample quality, measured by quantitative mRNA expression analysis.
Introduction 18
In 2008, a biobank was founded at the Asklepios Clinics in Gauting, a clinic to RNAlater TM (Quiagen, Hilden, Germany). RNAlater samples were left at 4 °C for 24 66 h or 7 days, before the RNAlater was discarded and samples were stored dry at -80 67°C without snap freezing. Thus, a set of 12 samples (4 time points and 3 methods) 68 was generated for each patient. (Fig 1) . performed by the alternating regressions approach to account for repeated 126 measurements and assuming a constant bias in the conversion of methods (4). All 127 statistical tests were conducted on two-sided, exploratory 5% significance levels. Pathological examination is critical before using archived human material. We 140 compared HE-stained slices of fresh frozen or RNAlater preserved tissue. To be able 141 to cut tissue samples treated with RNAlater, it turned out to be necessary to cool the 9 142 cryostat to -30 °C to ensure the sample kept frozen, and to use tempered blades 143 normally used to cut hard tissues like bone. Doing so, we were able to cut these 144 tissues without removing RNAlater. Both -tissue that was snap frozen and tissue 145 preserved in RNAlater, were equally well suited for histological evaluation (Fig. 2 for a method or shorter ischemic times (Table 3) . Scatter plots as well show no 212 evidence for a trend in ischemic time (Fig. 6 ).
213
To further evaluate the conformance of the methods, we performed Bland-Altman 214 analyses (Fig. 7) . Agreement between RNAlater RNA-preserving methods is slightly 217 freezing method (95% of expected relative deviations lie between 0.33 and 2.38), but 218 there is no evident trend favoring one or the other method. In conclusion, RNAlater is a protective reagent with many in the context of clinical 
